Therapeutic strategies for triple-negative breast cancer.
about
Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB familyAntimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2/9 by Blocking NF-κB and ERK/MAPK Signaling PathwaysThe integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers.C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approachesTriple-negative breast cancer.Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancerCharacteristics of triple-negative breast cancerAssociation of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapyTriple negative breast cancers have a reduced expression of DNA repair genesPolymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.Triple-negative breast cancer: are we making headway at least?Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical featuresAssociation between mesothelin expression and survival outcomes in patients with triple-negative breast cancer: a protocol for a systematic review.Biomarkers for Basal-like Breast Cancer.Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.Adjuvant therapy of triple negative breast cancer.Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.Triple-negative breast cancer: present challenges and new perspectives.Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer.Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells.AKR1B10 overexpression in breast cancer: association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.Expression of androgen receptors in primary breast cancer.Lymphangiogenic characteristics of triple negativity in node-negative breast cancer.Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
P2860
Q28258227-2F0CF502-F66E-44A0-8086-222603B644CCQ28546871-5D4E351B-6A8C-4490-95D9-A94EAF34150CQ30992805-4FC856AC-2A95-4432-918D-D72E238D177DQ33966470-4FEF6E4F-4792-448A-A99D-B8BEAD533A4BQ34095802-8B8E9222-78DD-490C-88C4-195A54C2291AQ34119028-9AACE888-0458-41CF-ABDB-11745757B99CQ34274939-365A284D-146F-4BC5-80ED-97D4815A75E4Q34408090-224A004B-FA3E-441F-BCCE-7BF63E2CC4F9Q34479003-EEE977D7-F091-40A4-BF32-ECA3F8F3F50EQ34760876-1A24DB6C-A3CB-400B-84D2-C36668753837Q34794035-8D1C9F2C-0EDC-4EC5-A598-C885E4ABB3F6Q35919277-6B804190-6EB1-4FBB-809D-C9935D50352BQ36061177-A52B1CB1-2934-4785-9E30-85F54E66C54AQ36914825-D4A2A284-AB75-458C-B47A-B700FFF9CE66Q37170197-72F68D31-B8A8-4A9E-9E4C-DC8DE2C2A095Q37328394-F54FA8AC-41AB-4C80-82CC-EC16E7EDDBE9Q37563378-0D61E254-5308-46FC-902D-121B68172986Q37571648-D58DC98D-C905-4627-A95D-598BACCAF075Q37687380-884284FD-6771-4318-8FB2-13BA7B62D8ADQ37764168-F5C6E3D6-3C89-4EFD-B4AE-9F537D6EEA97Q37775105-D04788E5-6572-4F9D-8CF8-61F0F4721724Q38753533-42E52680-A06D-4871-8B70-2328E826DC60Q38830186-BCB90B77-1061-4676-A3AC-2AA64E286BFDQ39357739-8EA1DE46-7EFB-4F04-A215-0196EBF0FE55Q43246075-D3A3D604-21BD-4C4F-BBFF-3CB839045A45Q43249156-87A3CF51-2E44-4B43-A5B2-297242C28D3DQ45984042-3A95E1FE-4729-4826-86A4-8DF7D32A8E24Q50860074-17DC5DA2-A50C-4121-A2D3-BE65005D2762Q51036885-1FF1388C-592C-46F7-8481-FBAFE9111159Q54537693-25B2066A-C46C-49CD-BDD8-C441054CA938
P2860
Therapeutic strategies for triple-negative breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Therapeutic strategies for triple-negative breast cancer.
@en
Therapeutic strategies for triple-negative breast cancer.
@nl
type
label
Therapeutic strategies for triple-negative breast cancer.
@en
Therapeutic strategies for triple-negative breast cancer.
@nl
prefLabel
Therapeutic strategies for triple-negative breast cancer.
@en
Therapeutic strategies for triple-negative breast cancer.
@nl
P1433
P1476
Therapeutic strategies for triple-negative breast cancer.
@en
P2093
Antoinette R Tan
Sandra M Swain
P304
P356
10.1097/PPO.0B013E31818D839B
P577
2008-11-01T00:00:00Z